Octagon Capital Advisors LP / BBIO
Octagon Capital Advisors LP’s Bridgebio Pharma Inc Position
Does Octagon Capital Advisors LP own Bridgebio Pharma Inc (BBIO)? Not currently — the last reported position was 441.6K shares worth $12M in Q4 2024; the fund’s latest 13F (Q1 2026) no longer reports it.
Position Value
$12M
Q4 2024
Shares
441.6K
% of Portfolio
+1.99%
Quarters Held
15
position exited
Position History BBIO
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q4 2024 | 441.6K | $12M | +1.99% |
| Q3 2024 | 552.0K | $14M | +2.19% |
| Q2 2024 | 690.0K | $17M | +2.75% |
| Q1 2024 | 690.0K | $21M | +2.56% |
| Q4 2023 | 706.8K | $29M | +4.57% |
| Q3 2023 | 971.6K | $26M | +3.94% |
| Q2 2023 | 1.22M | $21M | +2.92% |
| Q1 2023 | 1.34M | $22M | +3.19% |
| Q4 2022 | 933.7K | $7M | +1.11% |
| Q3 2022 | 933.7K | $9M | +1.60% |
| Q2 2022 | 933.7K | $8M | +2.26% |
| Q1 2022 | 2.27M | $23M | +4.98% |
| Q4 2021 | 1.77M | $29M | +5.74% |
| Q3 2021 | 569.4K | $27M | +6.57% |
| Q2 2021 | 380.9K | $23M | +4.81% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Octagon Capital Advisors LP’s full portfolio or all institutional holders of BBIO.